News

A committee of the European Medicines Agency (EMA) is recommending the refusal of marketing authorization for Nouryant (istradefylline) — approved as Nourianz in the U.S. — as a medication for treating off episodes in Parkinson’s disease in the EU. In its opinion, the Committee for Medicinal Products for Human…

Blood levels of various fat molecules — known as the lipid profile — in people with familial Parkinson’s disease caused by mutations in the GBA gene differ from those seen in people with sporadic Parkinson’s and healthy individuals, a study reported. These findings suggested that problems with lipid metabolism…

Digital health technology, which spans phone apps to telemedicine, is advancing Parkinson’s disease research and clinical care, according to different review studies. “Digital health technology is an important and promising field that is beginning to make a real tangible impact on persons with [Parkinson’s disease],” Anat Mirelman, PhD, a…

Virtual reality video gaming was helpful and useable as an exercise tool, and demonstrated positive patient satisfaction with no adverse effects among four people with mild to moderate Parkinson’s disease, a case study reported. While previous studies have found limitations with using video games among “more fragile groups,” such…

Forest Hills Lab announced that it has U.S. Food and Drug Administration (FDA) permission to open a Phase 2 trial into the tolerability and potential efficacy of FHL-301 in people in the early stages of Parkinson’s disease. The double-blinded trial will randomly assign patients to the investigative treatment or to a…

The Parkinson’s Foundation is making an effort to put patients at the center of clinical research, both through its Research Advocates program and more recently, patient advisory boards, funded by the Patient-Centered Outcomes Research Institute (PCORI). Since 2008, the foundation’s advocacy program has trained more than 300…

The U.S. Food and Drug Administration (FDA) has given fast track designation to the investigational cell therapy DA01, now in a clinical trial in people with advanced Parkinson’s disease. Developed by BlueRock Therapeutics, a wholly owned subsidiary of Bayer, DA01 is made up of dopamine-producing nerve cells derived from…

Ipsen has entered into an exclusive worldwide licensing agreement with Integrative Research Laboratories (IRLAB) to develop and commercialize mesdopetam, an experimental therapy for reducing levodopa-induced dyskinesia, or involuntary movements, in people with Parkinson’s disease. “We are excited to enter this licensing agreement with IRLAB. By working in partnership,…

The number and severity of non-motor symptoms increase during the early stages of Parkinson’s disease, and are significantly associated with age and motor symptoms, according to a study in China. The findings showed that a higher non-motor symptom burden in early Parkinson’s was significantly associated with a faster progression…